Patents Assigned to Erasmus University Medical Center Rotterdam
-
Publication number: 20170137899Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: ApplicationFiled: January 12, 2017Publication date: May 18, 2017Applicant: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Publication number: 20170101684Abstract: The disclosure is in the field of medical treatments and relates to the treatment of cancer, in particular, multiple myeloma (MM). Even more in particular, it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular, subjects with a poor prognosis. In a particular embodiment, the disclosure provides a method of treatment wherein subjects with a poor prognosis are selected and treated with a proteasome inhibitor such as Bortezomib. The disclosure further provides means and methods for identifying subjects with a poor prognosis. More in particular, the disclosure provides a composition comprising a proteasome inhibitor for use in the treatment of a subject with multiple myeloma when the subject has been diagnosed with an amp1q chromosomal aberration.Type: ApplicationFiled: March 28, 2015Publication date: April 13, 2017Applicants: Erasmus University Medical Center Rotterdam, Skylinedx B.V.Inventors: Martinus Hendrikus Van Vliet, Pieter Sonneveld
-
Patent number: 9567653Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: GrantFiled: August 14, 2014Date of Patent: February 14, 2017Assignee: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Publication number: 20160273053Abstract: The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level of methylation in said CpG island of a control subject, is indicative of said CpG island being hypermethylated.Type: ApplicationFiled: March 21, 2016Publication date: September 22, 2016Applicant: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Ellen Catharina ZWARTHOFF, Annechiena Geertruide VAN TILBORG
-
Patent number: 9376726Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.Type: GrantFiled: May 5, 2014Date of Patent: June 28, 2016Assignee: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Aurelia Haller, Roderick Tang
-
Patent number: 9334519Abstract: The present invention relates to a method for characterizing the antibiotic resistance of a microorganism, the method comprising the steps of (a) providing a reference mass spectrum of an antimicrobial compound, its enzymatic modification product, its molecular target, or of a substrate compound of a its modifying enzyme; (b) exposing a microorganism, a cell lysate thereof, or a growth medium supernatant thereof, to the antimicrobial compound or the substrate compound in aqueous liquid to thereby provide an exposed sample; (c) acquiring a mass spectrum of the exposed sample; (d) comparing the mass spectrum acquired in step c) with the reference mass spectrum of step (a), and (e) determining from the comparison whether modification of the antimicrobial compound, its modification product or its molecular target or of the substrate has occurred following the exposure, and establishing that the microorganism is potentially resistant to the antimicrobial compound when the modification is observed.Type: GrantFiled: March 10, 2015Date of Patent: May 10, 2016Assignee: Erasmus University Medical Center RotterdamInventors: Theo M. Luider, Jeroen van Kampen, Alexander F. Van Belkum, Wilhelm Goessens, Gero P. Hooff
-
Patent number: 9334543Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.Type: GrantFiled: November 25, 2014Date of Patent: May 10, 2016Assignee: Erasmus University Medical Center RotterdamInventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Jan Groen
-
Patent number: 9328144Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: May 10, 2013Date of Patent: May 3, 2016Assignees: UNIVERSITY OF WASHINGTON, Erasmus University Medical Center Rotterdam (Erasmus MC)Inventors: David M. Koelle, George M. G. M. Verjans
-
Patent number: 9012174Abstract: The present invention relates to a method for characterizing the antibiotic resistance of a microorganism, said method comprising the steps of (a) providing a reference mass spectrum of an antimicrobial compound, its enzymatic modification product, its molecular target, or of a substrate compound of a its modifying enzyme; (b) exposing a microorganism, a cell lysate thereof, or a growth medium supernatant thereof, to said antimicrobial compound or said substrate compound in aqueous liquid to thereby provide an exposed sample; (c) acquiring a mass spectrum of the exposed sample; (d) comparing the mass spectrum acquired in step c) with the reference mass spectrum of step (a), and (e) determining from said comparison whether modification of said antimicrobial compound, its modification product or its molecular target or of said substrate has occurred following said exposure, and establishing that said microorganism is potentially resistant to said antimicrobial compound when said modification is observed.Type: GrantFiled: August 19, 2010Date of Patent: April 21, 2015Assignee: Erasmus University Medical Center RotterdamInventors: Theo M. Luider, Jeroen van Kampen, Alexander F. Van Belkum, Wilhelm Goessens, Gero P. Hoof
-
Publication number: 20150050668Abstract: The present invention relates to a method for determining the presence of anti-Tr antibodies in a subject comprising the steps of obtaining a sample from said subject testing the presence of said antibodies in said sample by addition of DNER protein or an antigenic part thereof and checking whether said DNER protein is bound by any antibodies in said sample Such an assay is useful for the diagnosis of paraneoplastic cerebellar degeneration that is associated with Hodgkin lymphoma, or, more generally, to type patients suffering from cerebellar ataxia. Also comprised in the invention is a kit for performing such an assay.Type: ApplicationFiled: March 1, 2012Publication date: February 19, 2015Applicant: Erasmus University Medical Center RotterdamInventors: Petrus Abraham Elisa Sillevis Smitt, Esther De Graaff
-
Publication number: 20140336734Abstract: The invention relates to a hyperthermia system for treating a patient, comprising an RF power unit, one or more RF antenna's connected to the RF power unit for generating a focused three-dimensional RF field, a controller for adjusting the RF power source and/or the one or more RF antenna's for steering the focused three-dimensional RF field; a sensor for sensing a parameter representative of the focused three-dimensional RF field; a communication environment for inputting data from the said sensor and/or additional information provided by the patient, said communication environment being capable of generating trigger signals to the controller for in use steering the focused three-dimensional RF filed in real time. The invention further relates to a method for generation a focused three-dimensional RF field.Type: ApplicationFiled: August 19, 2011Publication date: November 13, 2014Applicant: Erasmus University Medical Center RotterdamInventors: Gerard Cornelis van Rhoon, Margarethus Marius Paulides, Jurriaan Fokke, Roelf Albert Roskam
-
Publication number: 20140322715Abstract: The invention comprises a method to determine the chance of a successful pregnancy based on the ratio of said ratio indicated as a formula that uses the presence of Lactobacillus and Staphylococcus bacteria in relation to the total amount of bacteria in a sample of a subject, preferably a urine sample. Also comprised in the invention is a kit, preferably a qPCR kit, for performing the method of the invention and outputting the result. Such a method and kit are particularly advantageous for predicting the chance of a successful pregnancy in subjects undergoing or eligible for an artificial insemination method such as IVF or ICSI.Type: ApplicationFiled: August 12, 2011Publication date: October 30, 2014Applicant: Erasmus University Medical Center RotterdamInventors: Dirk Jan Kok, Jozef Stephanus Elisabeth Laven, Delshad Mama Maghdid, Nicole Geertje Maria Beckers
-
Publication number: 20140315749Abstract: The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy.Type: ApplicationFiled: November 15, 2011Publication date: October 23, 2014Applicants: Erasmus University Medical Center Rotterdam, Universidad De SalamancaInventors: Menno Cornelis van Zelm, Jacobus Johannes Maria van Dongen, José Alberto Orfao de Matos Correia e Vale
-
Publication number: 20140287943Abstract: The present disclosure is directed to detecting colon disorders by measuring the expression of SHIP1 in a sample of PBMCs. One method includes the following steps, obtaining a sample including peripheral blood mononuclear cells (PBMCs) from a subject and determining whether SHIP1 is underexpressed in the PBMCs or lacks normal enzymatic activity. The present disclosure is also directed to a method of determining the expression of SHIP1 protein expression and SHIP1 enzyme activity in PBMCs. This method includes the following steps, obtaining a sample comprising PBMCs from a subject and determining the amount of SHIP1 in the PBMCs.Type: ApplicationFiled: April 27, 2012Publication date: September 25, 2014Applicants: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: William G. Kerr, Gwenny M. Fuhler, Sandra Fernandes
-
Patent number: 8833133Abstract: A test apparatus for evaluating a measuring device for measuring a diffusion capacity of a person's lungs by measuring a change of concentration of a gas species in a mixture, when the mixture is inhaled and subsequently exhaled by a person, wherein the test apparatus includes (a) a port for connecting to the measuring device; (b) a compartment coupled to the port; (c) a circulation circuit configured to circulate gas from the compartment back to the compartment; and (d) a gas species removing element configured to selectively reduce a partial pressure of the gas species at a point in the circulation circuit.Type: GrantFiled: June 1, 2010Date of Patent: September 16, 2014Assignee: Erasmus University Medical Center RotterdamInventors: Antonius Fransiscus Marie Verbraak, Wilhelmus Petrus Johannes Holland
-
Publication number: 20140221313Abstract: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the invention provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92 gene classifier.Type: ApplicationFiled: July 12, 2012Publication date: August 7, 2014Applicant: Erasmus University Medical Center RotterdamInventors: Rowan Kuiper, Pieter Sonneveld
-
Publication number: 20140107951Abstract: The invention relates to a method to determine the wavelength dependent absorption coefficient of a turbid medium using overlapping illumination-detection areas comprising the steps of a) retrieving a calibration spectrum (CA) from a reference measurement using a reference sample; b) carrying out a measurement on an actual sample for determining the absolute reflection spectrum (Rabs) using a raw spectrum measured on the sample (Smedium) and the calibration spectrum (C?); C) using the absolute reflection spectrum (Rabs) for determining the wavelength dependent absorption coefficient by minimizing the difference between the measured absolute reflection spectrum (Rabs) and a model function (Rabsmodel).Type: ApplicationFiled: March 26, 2012Publication date: April 17, 2014Applicant: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Henricus Josephus Cornelus Maria Sterenborg, Stephen Chad Kanick, Arjen Amelink, Dominic James Robinson
-
Publication number: 20140024019Abstract: The invention relates to the field of medical diagnostics. Provided are methods and kits for determining the health status of a subject, for early detection of tissue damage, for early diagnosis and monitoring of a disease, and/or for evaluation of treatment effectiveness in a subject using circulating tissue macrophages (CTM) as a mirror of disrupted tissue homeostasis and disease.Type: ApplicationFiled: March 5, 2012Publication date: January 23, 2014Applicants: Universidad de Salamanca, Erasmus University Medical Center RotterdamInventors: Jacobus Johannes Maria Van Dongen, José Alberto Orfao De Matos Correia E Vale
-
Publication number: 20130096025Abstract: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma.Type: ApplicationFiled: May 27, 2011Publication date: April 18, 2013Applicant: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventor: Pieter Sonneveld
-
Patent number: 8420886Abstract: The invention relates to an animal model of cardiovascular disease and a method of preparation and use thereof. In particular, it relates to a genetically engineered animal model of aortic aneurysms and methods for screening drugs using the animal model. Provided is a genetically-modified, non-human mammal, wherein the modification results in a disrupted Fibulin-4 gene. Also provided is a genetically-modified animal cell containing a disrupted Fibulin-4 gene. The mammal or animal cell can be used as a model for a cardiovascular condition or disease, preferably aortic aneurysm, more preferably thoracic aortic aneurysm. Furthermore, methods for identify or validating a compound that can be used to treat or to prevent an aberrant cardiovascular condition are provided, as well as method to identify a gene involved in the response to aortic failure.Type: GrantFiled: July 22, 2005Date of Patent: April 16, 2013Assignee: Erasmus University Medical Center RotterdamInventors: Jeroen Essers, Georgios Aris Garinis, Roland Kanaar